Matheson Advises Royalty Pharma On Revised $6.5 Billion Hostile Bid For Elan

Author:Mr Tim Scanlon, George Brady and Fergus Bolster

Matheson continues to advise Royalty Pharma on its $6.5 billion cash offer for Elan Corporation plc, the Irish biotechnology company. On 20 May 2013, Royalty Pharma revised its hostile offer for the NASDAQ-listed Elan Corporation.

The Matheson team is led by Tim Scanlon, George Brady and Fergus Bolster.

This is the latest in a number of high-profile multi-billion dollar transactions that Matheson has advised on.

Matheson is also advising the US pharmaceutical firm Actavis on its $5.1 billion acquisition of Dublin-based Warner Chilcott. The all-stock deal was announced on 20 May 2013 and the acquisition is expected to be completed by the end of the year.

In February of this year, Matheson advised on the sale of the country's biggest life and pensions provider Irish Life to Canada Life parent, Great-West Lifeco. The firm advised Ireland's Minister for Finance on the1.3 billion sale, which...

To continue reading